

# Africa Health Security Architecture

A cesspool of Corruption, Conflicts of Interest and Corporate Greed

#### Africa Health Security Architecture: A cesspool of Corruption, Conflicts of Interest and Corporate Greed

**Policy** Makers & **Distributors** 





















**Policy** 

**Enforcers** 

**African Regulatory Platforms** 

**Partnerships for African** Vaccine Manufacturing (PAVM) Framework for Action





Africa Vaccine **Acquisition Task Team** (AVATT)


**Africa Vaccine Acquisition Trust (AVAT)** for COVID-19 vaccines





Corporate **Partners** 

> Vaccine Hubs



**P**fizer

**mRNA** 

Hubs







**African Vaccine** 

**Regulatory Forum** 



**African Export-**

**Import Bank** 









#### Partnerships for African Vaccine Manufacturing: Conflicts of Interest

#### **PAVM Advisory Group**



Ms. Ahunna Eziakonwa UNDP – Chief of Africa



Adesina AfDB – President

Dr. Akinwuni



Pr. Benedict O. Oramah Afreximbank – President



Mrs. Eva Kadili UNICEF – Director Supply Division



Dr. Francis Collins NIH, USA – Director



Dr. George F. Gao China CDC – Director General



Dr. Githinji Gitahi AMREF – CEO



Ms. Glaudina Loots Health Science Dpt of Science and Innovation – Director



Dr. John N. Nkengasong AfCDC – Director



Prof. Kayum Ahmed OSF – Division Director



Mr. Martin Seychell Team Europe Initiative – Deputy Director General



Dr. Ngozi Okonjolweala WTO – Director General



Dr. Olive Shisana South African Presidency – Senior Advisor to the Presiden of South Africa



Pr. Peter Piot Former Director at London School of Hygiene and Tropical Medicine



Mrs. Reeta Roy MCF – CEO



Dr. Richard Hatchett CEPI – CEO



Mr. Samaila Zubairu AFC – President



Dr. Seth Berkley Gavi – CEO



Dr. Soumya Swaminathan WHO – Chief Scientist



Mr. Strive Masiyiwa Econet Global – Executive Chairman



Dr. Trevor Mundel BMGF – President, Global Health



Dr. Vera Songwe UNECA – Executive Secretary



Dr. Wade Abel LANAVET – Director General



Mrs. Winnie Byanyima UNAIDS Executive – Director

#### Diseases prioritized by PAVM/FFA



#### Diseases prioritized by WHO

World Health Organization

**Health Topics >** 

Countries ~

Newsroom ∨

Emergencie

At present, the priority diseases are:

- COVID-19
- · Crimean-Congo haemorrhagic fever
- · Ebola virus disease and Marburg virus disease
- Lassa fever
- Middle East respiratory syndrome coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS)
- · Nipah and henipaviral diseases
- Rift Valley fever
- Zika
- "Disease X"

This is not an exhaustive list, nor does it indicate the most likely causes of the next epidemic. WHO reviews and updates this list as needs arise, and methodologies change. Based on the priority diseases, WHO then works to develop R&D roadmaps for each one.

\* Disease X represents the knowledge that a serious international epidemic could be caused by a pathogen currently unknown to cause human disease. The R&D Blueprint explicitly seeks to enable early cross-cutting R&D preparedness that is also relevant for an unknown "Disease X".

The African Development Bank (AfDB), African Pharmaceutical **Technology Foundation (APTF) in** association with the African Union, will assist African pharmaceutical companies to scout for technologies and negotiate with global pharma to facilitate the local production vaccines, drugs, diagnostics, and therapeutics.

# African Pharmaceutical Technology Foundation (APTF)









Mission

To facilitate and speed up vaccine delivery, clinical trial approvals

**National lot release by WHO-contracted laboratories** 





### Regulatory Partnerships



**Prequalification of Medicines Programme** 



**International Council for Harmonisation** 



**International Medical Device Regulators Forum** 





**African Vaccine Regulatory Forum** 









**African Medicine Regulatory Harmonisation** 









# WHO Afro Marketplace

# Africa Innovators Network

ALLO SANTE	GIC Space	Healthbotics Limited		MobiCare	Umubyeyi	
Côte d'Ivoire	Cameroon	Nigeria		Uganda	Rwanda	
Service Microscopy		Virtual Digital Assistant using AI and blockchain technology for Clinical Documentation		Mobile Based Platform Access and consult doctors	Digital Health Platform for Maternal and Child health through the web, mobile, and mobile social media channels	
H&S Technologie	es Using Data-Di Algorithms to False Data En	Detect	Uganda Vacc+	DigiMat DigiTrack	V-safe After Vaccination Health Checker	
Cameroon	United states of	America	Uganda	Nigeria	Centers for Disease Control and Prevention	
Medical equipment using 3D Technology	Identify potentiall digital vaccination	•	OpenSRP + RapidPro for health workers	Calibrated weighing automatically transr quantities in real tin	nit vaccine	



### African Union Smart Safety Surveillance (AU-3S) Programme





#### **Partners**

BILL & MELINDA
GATES foundation



Medicines & Healthcare products Regulatory Agency



AU-3S programme is a Data Integration and Signal Detection (DISD) system, enabling in-country and cross-country near real-time access, downstream analysis and signal detection. To date, the programme has worked to improve electronic reporting for adverse events following immunization (AEFIs) by incorporating an AEFI form in the Med Safety App launched in 2021.

MedSafety App is available to over 400 million people for AEFI and Adverse Events of Special Interest (AESI) reporting, which has increased safety reporting for vaccines by 8-fold in the AU-3S pilot countries

SAHPRA launched (22 April 2021) the MedSafety App, a WEB-RADR project, a collaboration between the World Health Organisation (WHO), the WHO Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (UMC), and the UK Medicines and Health products Regulatory Agency (MHRA),







AU-3S programme currently pilots its approach in Ethiopia, Ghana, Kenya, Nigeria and South Africa










#### **African Union Special Envoy on Covid-19**











#### Dr Ngozi Okonjo-Iweala: 'Global Elitist Hack'

WØRLD ECONOMIC

WEF/Agenda Contributor

**Young Global Leader** 





**Board of Trustees (since 2009)** 





Member of the Board



the



**Global Education Opportunity** 

Member



**Board Member** 















**Development Economist** 



**Director-General** 



**External Advisory Group** 

**Member of Finance Committee** 

(2003-2006, 2011-2015)




**African Development Bank** 

Member of the International **Advisory Panel (since 2016)** 



#### **Africa Health Security Architecture**

A cesspool of Corruption, Conflicts of Interest and Corporate Greed



#### William Kwabena Ampofo

#### **Chairman AVMI**

WHO International Health
Regulations Steering Committee
WHO Food and Drugs Authority
Technical Advisory Committee
on Vaccines and Biologicals
WHO Global Influenza
Programme Technical Advisor
WHO IHR Emergency Committee
on Ebola



#### **Dr Simon Agwale**

#### **Director AVMI**

CEO of Innovative Biotech
US Vaccine Research NIH and CDC
Lead of Bold Program 4
Partnerships for African Vaccine
Manufacturing (PAVM)
Member of The European and
Developing Countries Clinical
Trials Programme (EDCTP)

WHO ECOWAS vaccines taskforce



#### **Patrick Tippoo**


#### **Executive Director AVMI**

**Chief Science and Innovation Officer BIOVAC** 

Lead, Vaccine Manufacturing Enterprise Working Group within the AU Covid-19 Commission

Vice-President of the Developing Country Vaccine Manufacturers Network

Chair of the Emerging Biopharmaceuticals
Manufacturing Network (EBPMN)



#### Ms Tolu Disu

#### **Director AVMI**

Vaccines Basic Research with Merck 2009





## Influence

#### The South African Health Architecture

A Cesspool of Corruption, Corporate Greed and Conflicts on Interest

**Policy** Makers & **Distributors** 









#### **Policy Enforcers**



















**South African Government** 









#### **Corporate Partners**



**BLACKROCK** 









Discovery

Health



























**X** Rothschild & Co















### **Country Cooperation Strategy**

#### **South Africa**

STRATEGIC PRIORITY 4:

and development

Support South Africa in meeting its global health obligations while

contributing to international health

**Updated May 2018** 

atr	, 1	annen
aic	gu	ance

Strategic Priorities	Main Focus Areas for WHO Cooperation				
STRATEGIC PRIORITY 1 Strengthening national efforts towards the attainment of Universal Health Coverage (UHC)	Support the phased institutionalization of the NHI and specifically advance the National Health Insurance Fund     Support the optimal distribution and effective utilization of the health workforce     Strengthen the national regulatory authority (NRA) to ensure access to safe quality medical products and food				
STRATEGIC PRIORITY 2 Contribute towards reduction of the burden of communicable diseases, especially HIV, TB, STIs, hepatitis and vaccine-preventable diseases	<ul> <li>Strengthen capacity for scaling-up prevention, treatment and care for HIV, STIs and Hepatitis, including measures to promote adherence and prevent drug resistance</li> <li>Strengthen the prevention and treatment of TB, including M/XDR-TB to reduce the incidence, prevalence, and case fatality rates</li> <li>Promoting access to existing and new immunization products to reduce vaccine-preventable diseases</li> </ul>				
STRATEGIC PRIORITY 3: Support the prevention and control of noncommunicable diseases, mental health disorders, violence and injuries	Support improved management of the four main noncommunicable diseases (NCDs), namely cardiovascular diseases, cancers, diabetes and chronic respiratory diseases, in order to reduce morbidity and mortality				

#### Support progress towards disease elimination and eradication Support the reduction of maternal and neonatal mortality in order to meet the SDGs and other international Commitments

Support the implementation of International Health Regulations (2005)

WHO COUNTRY COOPERATION STRATEGIC AGENDA (2016–2020)




#### WHO Collaborating Centres Global database

#### South Africa

Reference	Institution name	<u>City</u>	<u>Country</u>	Region	<u>Title</u>	WHO responsible officer
SOA-48	University of Pretoria	Pretoria,	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Prevention of Deafness and Hearing Loss	CHADHA Shelly
SOA-49	University of the Free State	Bloemfontein	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Vaccine Preventable Diseases Surveillance and Pathogens Genomics	MATHIU Jason Mwenda
SOA-38	University of KwaZulu-Natal	Durban	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Pharmaceutical Policy and Evidence Based Practice	IYENGAR Swathi Bhargav
SOA-43	National Institute for Communicable Diseases	Johannesburg	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Antimicrobial Resistance	COULIBALY Sheick Oumar
SOA-47	University of Cape Town	Cape Town	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Trachoma	SOLOMON Anthony
SOA-14	University of South Africa (UNISA)	Pretoria	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Postgraduate Distance Education and Research in Nursing and Midwifery Development	ASAMANI James Avoka
SOA-39	Stellenbosch University	TYGERBERG	SOUTH AFRICA	AFRO	WHO Collaborating Center for Bioethics	REIS Andreas Alois
SOA-45	University of Pretoria	Pretoria	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Health in all Policies and Social Determinants of Health	PHORI Peter Malekele
SOA-18	University of Western Cape	Cape Town	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Research and Training in Human Resource for Health Development	AHMAT Adam
SOA-34	University of Cape Town	Cape town	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Mental Health and Psychiatry	GRAY Brandon
SOA-13	University of Natal	Durban	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Educating Nurses and Midwives in Community Problem- solving	ASAMANI James Avoka
SOA-27	National Institute for Occupational Health (NIOH)	Johannesburg	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Occupational Health	PEGA Frank
SOA-50	Sefako Makgatho Health Sciences University	Pretoria	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Diarrhoeal Diseases Research and surveillance	MATHIU Jason Mwenda
SOA-5	University of Western Cape	Cape Town	SOUTH AFRICA	AFRO	WHO Collaborating Centre for Oral Health	MAKINO Yuka

#### **SA Academia Collaborating with WHO – A case for Conflicts of Interest**



CIDER made World Health Organization (WHO) Collaborating Centre for HIV Epidemiology and Research




### South African National Control Laboratory for Biological Products




List of WHO-contracted laboratories performing testing on behalf of WHO Regulation and Prequalification Department / Laboratory Networks and Services Team (Version: 29June 2021)

Laboratories	Country	Physical testing on behalf of WHO /Vaccine component / Tests
South Africa National Control Laboratory for Biological Products, University of the Free State https://www.ufs.ac.za/health/de partments-and- divisions/national-control- laboratory-for-biological- products-home  Postal address: Internal Box G49 University of the Free State PO Box 339, Bloemfontein 9300 SOUTH AFRICA	South Africa	Oral Poliomyelitis group of vaccines: Potency/ thermal stability Measles: Potency/ thermal stability Yellow Fever: Potency/ thermal stability Covid-19:

#### South African National Control Laboratory for Biological Products Conflicts of Interest



#### **SA Academia Collaborating with WHO – A case for Conflicts of Interest**



WHO Collaborating Centre for HIV Epidemiology and Research





Regional reference laboratory for the World Health Organization (WHO) Vaccine-preventable Invasive Bacterial Diseases (VP-IBD) Coordinated Global Surveillance Network for the Southern African region



WHO-AFRO Regional Center of Excellence Bioinformatics











**Health Topics >** 

Countries >

Newsroom ∨

Emergencies >

Data v

Home / Publications / Overview / South Africa: South African antimicrobial resistance national strategy framework

South Africa: South African antimicrobial resistance national strategy framework

A One Health approach 2018-2024

2 January 2018 | Publication

SOUTH AFRICAN ANTIMICROBIAL RESISTANCE NATIONAL STRATEGY FRAMEWORK; A ONE HEALTH APPROACH 2018 – 2024 A (SA) national response to antimicrobial resistance is required to complement the development of a global action plan, as articulated in the World Health Organisation's (WHO) resolution EB134/37 "Combating antimicrobial resistance including antibiotic resistance", adopted by the World Health Assembly in May 2014.

Signature of Minister Of Health DR A MOTSOALEDI, MP MINISTER OF HEALTH Signature of Minister DAFF
MR S ZOKWANA, MP
MINISTER OF AGRICULTURE, FORESTRY
AND FISHERIES

MS MP MATSOSO DIRECTOR-GENERAL: HEALTH MR RM RAMASODI ACTING DIRECTOR-GENERAL: AGRICULTURE, FORESTRY AND FISHERIES

# Intergovernmental Negotiating Body (INB)


Conflicts of Interest



### World Health Organization Intergovernmental Negotiating Body



Co-Chairs of
Intergovernmental
Negotiating Body
(INB)
(February 24, 2022)



(South Africa)

- \* Member of the Executive Board of World Health Organisation
- \* Director General of the National Department of Health, SA

(Netherlands)

- \* Chair of the Global Health Security Agenda
- \* Vice-President, Conference of the Parties representing the European Region

The INB was established to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response focused on a new revised International Health Regulations

#### Dr Precious Matsoso - "Global Elitist Hack" - Conflicts of Interest



Chair

**Policy Review** Committee



**Honorary Lecturer** 

**Department of Pharmacy & Pharmacology** 



Former Registra

**Medicines of** the National Drug Regulatory Authority



Chair

**Ministerial Advisory** Committee on e-Health



**Director-General** 

REPUBLIC OF SOUTH AFRICA

health

Department:

**Chair of Technical National Health Council** 



Member

**Health Regulatory Science Platform** 



**WHO Executive Board Member** 



Technical **Cooperation for Essential Medicines** and Traditional Medicines



**Dr Precious Matsoso** 





Co-Chair

**Digital Health Technical Advisory** 

**World Health** 

Organization


Director

**Public Health** 

Innovation and

Intellectual

**Property** 




Group



Member

UN High-Level Panel on Access to Health Technologies





Member

Member

**NCD** Alliance



Vice-Chair

Anti-Microbial **Resistance Committee** 

Think Global Health

COUNCILon

**RELATIONS** 

**FOREIGN** 



Member

**Commission on High Quality Health Systems** 



Author







**World Health** 

Global Governance **Project Author** 

RESOLVE TO SAVE LIVES **Board of Directors** 


"It will require goodwill and commitment from countries. Where countries don't commit, we will have to use other measures. We might look at whether we want to impose sanctions on those countries or come up with incentives"

**Dr Precious Motsoso** 

Co-Chair at the WHO Pandemic Prevention Preparedness and Response










### Recipients of mRNA technology from the WHO mRNA technology transfer hub







#### mRNA Technology Transfer Hub Funders A Case for Conflicts of Interest

supports the mRNA **Technology Transfer Hub Programme for the** production of mRNA vaccines

#### Steering Committee members (July 2022) - comprising of experts in mRNA vaccine development



**Marie-Paule Kieny** 

Chairs Board of Medicines				
Patent Pool Foundation				
Chair Board, Drugs for				
Neglected Diseases				
Initiative (DNDi)				
Wellcome Trust, Chair of				

the Strategic Advisory **Board on Vaccines and Drug-resistant Infections** 

**Board of Directors for the Human Vaccines Project** 

Member of European Vaccine Initiative till 2010

**Assistant Director-General** for Health Systems and Innovation at the WHO 2017

**Vaccine Research Director** WHO (2002 - 2010)

**Non-Executive Independent Director of BioMérieux** 

**Chair French Scientific Committee on COVID-19** vaccine

**Advisor GISAID (Global Initiative** on Sharing Avian Influenza Data) for the COVID-19 pandemic

**Global Antibiotic Research and Development Partnership** (GARDP), Member of the Board of Directors



**Mark Feinberg** 

President and CEO of IAVI
Medical Officer, Office of
AIDS Research at NIH

**Chief Public Health and** Science Officer, Merck

Vaccines

Member of the CEPI Joint **Coordinating Group** 

**Establishment The MSD-Wellcome Trust Hilleman** Laboratories

Fellow in the Advanced Leadership Initiative at Harvard University

Member, Council on **Foreign Relations** 

Chair of Interim Scientific Advisory Committee, **Collaboration for Epidemic Preparedness Innovations** (CEPI)

Acting Head, Clinical Development, for the Coalition of Epidemic Preparedness Innovations (CEPI) Global Clinical Research and Development teams at both Sanofi Pasteur and GlaxoSmithKline Biologicals



**Marion Gruber** 

**Vice President International AIDS Vaccine Initiative (IAVI)** 

Director, U.S. Food and Drug Administration (FDA) Office of Vaccine Research and Review (1992 to 2021)

FDA, Overseeing licensure and approval for COVID-19 vaccines

**Expert Advisor to WHO** 

Member, WHO Global Advisory **Committee on Vaccine Safety** 



**Professor of Clinical Research** and Pharmacovigilance



Michel de Wilde

Independent vaccine **R&D** vaccine expert Senior Vice President. **R&D**, Sanofi Pasteur (2001 - 2013)


Research Scientist, recombinant Hepatitis B vaccine, and GSK's Malaria vaccine candidate





Led the development of drugs

and vaccine



Senior Science Advisor, Africa CDC

https://medicinespatentpool.org/covid-19/mrna-technology-transfer-hub-programme/governance#Steering-Committee/



#### mRNA Technology Transfer Hub Funders A Case for Conflicts of Interest

supports the mRNA **Technology Transfer Hub Programme for the** production of mRNA vaccines

#### The mRNA Scientific Advisory Committee (mSAC) - comprising of experts in mRNA vaccine development



**Martin Friede** 

mSAC Chair

**Coordinator, Initiative** for Vaccine Research at the WHO

Vice President of **Vaccine Development** for Apovia Inc

**Lead vaccine delivery** research at Smithkline **Beecham Biologicals** 



**Duccio Medini** 

**R3 Program Director** at Wellcome Leap (Wellcome Trust and CEPI)

Senior Director, GSK - Vaccine R&D

**Director, Novartis** Vaccines, Vaccines R&D



Suhaib Siddigui

Former Director, Chemistry, Moderna Therapeutics Inc

Founder of Antirna Inc

**Vice President Technology** ZS Genetics, Inc.

**Director of Chemistry Helicos BioSciences** 

**Research Fellow National Institutes of** Health



**Barney Graham** 

**Former Deputy** Director of the NIAID Vaccine Research Center

**Chief of the Viral Pathogenesis** Laboratory, NIH

**Viral Pathogenesis** Laboratory, NIH partner with Moderna to develop Covid-19 vaccine



Chief Science Officer &	Chief Scientific Officer,
Global Head, External	Aeras (2017) funded by
Scientific Affairs, Sanofi	the Bill and Melinda
Vaccines	Gates Foundation
Lead Vaccine R&D,	Scientific Advisor Bill &
Merck Research	Melinda Gates Foundation
Laboratories	Global Health Program
Scientific Advisor	Scientific Advisor
USAID Malaria Vaccine	International AIDS Vaccine
Development Program	Initiative
Scientific Advisor HIV	Scientific Advisor NIH AIDS
Vaccine Enterprise	Vaccine Development

**Program** 



**Kiat Ruxrungtham** 

Scientific Chair of the **Chula Vaccine Research** Center (ChulaVRC)

**Director of the Covid19 Vaccine Development** Program, ChulaVRC

Lead Chula-Covid19 mRNA vaccine development program

#### WHO, Gates Foundation and South Africa join forces on Covid Vaccines



The programme focus; mRNA vaccines against COVID-19. Further development of other mRNA vaccines and therapeutics against important diseases that threaten LMICs.



**Health Topics >** 

Countries >

Newsroom ∨

Emergencies v

Data v

About WHO >

Home / News / New consortium working to boost vaccine production in South Africa

# New consortium working to boost vaccine production in South Africa

MPP, WHO, AFRIGEN, BIOVAC, SAMRC, and Africa CDC sign a letter of intent towards establishing the tech transfer hub in South Africa

30 July 2021 | Joint News Release | Geneva | Reading time: 3 min (902 words)

The Medicines Patent Pool (MPP) and the World Health Organization (WHO), Afrigen Biologics (PTY) Limited, the Biologicals and Vaccines Institute of Southern Africa (Biovac), the South African Medical Research Council (SAMRC) and Africa Centres for Disease Control and Prevention (Africa CDC) have signed a letter of intent to address the global imbalance of manufacturing capacity for COVID-19 vaccines.

#### WHO, Gates Foundation and South Africa join forces on Covid Vaccines

#### LETTER OF INTENT

BETWEEN THE WORLD HEALTH ORGANIZATION, THE MEDICINES PATENT POOL FOUNDATION, AFRIGEN BIOLOGICS (PTY) LIMITED, THE BIOLOGICALS AND VACCINES INSTITUTE OF SOUTH AFRICA, THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL,

AND THE AFRICAN CENTRES FOR DISEASE CONTROL AND PREVENTION

This Letter of Intent ("LOI") is made as of 29 July 2021 by and between the World Health Organization ("WHO"), a specialized agency of the United Nations responsible for international public health, whose headquarters is located at Avenue Appia 20, 1211, Geneva, Switzerland, Medicines Patent Pool Foundation ("MPP"), a non-profit foundation organised under the laws of Switzerland, whose business headquarters is located at Rue de Varembe 7, Geneva 1202, Switzerland, Afrigen Biologics (PTY) Limited ("Afrigen"), a with registration number 2014/135714/07, a company registered in South Africa with registered office at Unit 5&6 Kestrel Park, Longclaw Drive, Montague Gardens, 7441, Cape Town, South Africa, legally represented by Prof Aletta Petronella Susarah Terblanche the signatory hereto, The Biologicals and Vaccines Institute of Southern Africa ("Biovac"), a company duly registered under the laws of the Republic of South Africa with Registration number: 1998/011727/07 whose registered address being, 15 Alexandra Road, Pinelands, 7405, Cape Town, South Africa, the South African Medical Research Council ("SAMRC") a National Public Entity in terms of Schedule 3 of the Public Finance Management Act 1 of 1999 and statutory science council established in terms of Section 2 of the Medical Research Council Act 58 of 1991 with its principal place of business situated at: Francie Van Zyl Drive, Parow Cape Town represented herein by Professor Glenda Gray in her capacity as President, and the Africa Centres for Disease Control and Prevention ("Africa CDC"), together the "Parties," individually, a "Party":



















#### mRNA Technology Transfer Hub Partners: A Case for Conflicts of Interest



#### South African Government

www.gov.za



HOME	ABOUT	NEWSROOM	SERVICES	DOCUMENTS	JOBS	Q

Home » Newsroom » Media Advisories

World Health Organization Director-General, Dr Tedros Adhanom Ghebreyesus visits mRNA vaccine tech transfer hub in South Africa, 11-12 Feb

9 Feb 2022

WHO Director-General visits mRNA vaccine tech transfer hub in SA

The World Health Organization's (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus, will join Belgium's Minister of Development Cooperation, Ms Meryame Kitir, on a high-level visit to Cape Town, on 11-12 February, to visit the mRNA vaccine technology transfer hub and other facilities playing critical roles in the response to COVID-19 and protection of public health.

#### mRNA Technology Transfer Hub Partners: A Case for Conflicts of Interest




















#### WHO, Gates Foundation and South Africa join forces on Covid Vaccines

MANUFACTURING HOME ABOUT US \* PRODUCTS PRODUCT DEVELOPMENT **PARTNERSHIPS** JOIN OUR TEAM MEDIA CONTACT DETAILS \* DISCLAIMER



#### **Partnerships**

South African Council for

Scientific and Industrial Research (CSIR)

University of Cape Town

Sanofi Pasteur S.A.

The South African Department of Health

South African private sector health-service providers

**Developing Countries** Vaccine Manufacturers' Network (DCVMN)

African Vaccine Manufacturing Initiative (AVMI)

Africa (Pharmisa)

Industrial Development Corporation (IDC)


World Health Organization (WHO)

Pharmaceuticals Made in South

> United Nations Industrial Development Organization (UNIDO)

Neighbouring SADC Bionet-Asia Co. Ltd Pfizer Laboratories Countries

Program for Applied Technologies in Health (PATH)



# The South African Ministerial Advisory Committee on COVID-19, WHO and Gates Foundation Conflicts of Interest

Researcher	Institution	Role in MAC	Role in WHO	Principal Funder
Prof Salim Abdool Karim	The Centre for AIDS Programme of Research in South Africa (CAPRISA)	OVER-ARCHING CHAIR	WHO Science Panel WHO TB-HIV task force	Bill and Melinda Gates Foundation (BMGF)
Prof Quraisha Abdool Karim	CAPRISA	Public Health	Deputy-Chair, WHO Alliance for Sexual and Reproductive Health	BMGF
Prof Helen Rees	Chairperson, South African Health Products Regulatory Authority	Clinicians	WHO IHR Emergency Committee for COVID-19	BMGF
<b>Prof Wolfgang Preiser</b>	National Health Laboratory Service	Pathologists and Laboratory	Member of a WHO SARS mission to China	BMGF
Prof Lucille Blumberg	National Institute Communicable Diseases (NICD)	Clinicians	Committee for Review of the International Health Regulations during COVID-19	BMGF
Prof Shabir Madhi	Wits Health Consortium	CHAIR, Public Health	WHO, Strategic Advisory Group of Experts on Immunization, Vaccines and Biologicals (SAGE)	BMGF, Scientific Advisor
Prof Glenda Gray	South African Medical Research Council (SAMRC) President	CHAIR, Research	National Institute for Health, Wellcome Trust	BMGF
Prof Marc Mendelson	University of Cape Town	CHAIR, Clinicians	WHO Expert Panel on Drug Evaluation	BMGF
<b>Prof Francois Venter</b>	University of KwaZulu-Natal	Clinicians	WHO Advisor	BMGF
Prof Shabir Banoo	Right to Care	Clinicians	WHO Technical Consultant	BMGF

### Prof Salim Abdool Karim: A 'Global Élite' Puppet





**Advisor of Global Health** 







Africa Task Force For Coronavirus

African (🚗




Member

Steering Committee














AFRICA CDC



















- **WHO Science Council**
- Scientific Advisor to WHO **Director-General**
- HIV and Hepatitis Scientific and Technical Advisory Group
- **WHO HIV-TB Task Force**
- Chair of the Scientific and **Technical Advisory Group for** Reproductive Health







Fellow











**MRC HIV-TB Pathogenesis** and Treatment Unit















# **Prof Helen Rees**

Chairperson



# **Prof Helen Rees: WHO and 'Global Elite' Vaccine Hack**

Strategic and Technical Advisory Group on Infectious Hazards with Pandemic and Epidemic Potential (STAG-IH)

#### Member

SAGE focal point for HPV, Rubella, and HIV vaccines, and vaccine use in humanitarian emergencies Committee

#### Member

African Regional Immunisation Technical Advisory Group on Immunization (RITAG)

#### Chair

Wits RHI – WHO/UNAIDS Collaborating Centre in Reproductive Health and HIV

#### Lead Advisor

WHO/UNAIDS Steering Committee on Pre-exposure prophylaxis

Advisor

WHO Scientific and Technical Advisory Group on Infectious Hazards

#### Advisor

**Technical Advisory Committee on RSV Vaccines** 

#### Advisor

WHO Africa Regional Reproductive Health Task Force

#### Member

SAGE Committee on the Global Vaccine Action Plan

#### Member/Advisor

SAGE Committee evaluating progress towards the Decade of Vaccines


#### Member

SAGE Working Group on Measles and Rubella

#### Member

WHO IHR Emergency Committee for COVID-19

#### Member



Prof Helen Rees, OBE

WHO Global Strategic Advisory Group of Experts on Immunisation (SAGE)

#### Chair

PATH Maternal Influenza Immunisation Committee

**Chair Advisory Review Committee** 

International Health
Regulation Emergency
Committee on COVID-19

#### Chair

International Health Regulations Review Committee

#### Rapporteur

Review Committee on the Role of the IHR (2005) in the Ebola Outbreak and Response

#### Member (2015 to 2016)

SAGE Working Group on Ebola Vaccines

#### Chair

SAGE Committee on Ebola vaccines

#### Co-Chair

High Level Meeting on Ebola vaccines

#### Chair

IHR Emergency Committee on Yellow Fever

#### Member

IHR Emergency Committee on Polio

#### Chair (since 2014)

**Polio Research Group** 

#### Member

**TFI Working group on Ebola** 

#### Chair

WHO RSV Vaccine Consultation Expert Group

#### Advisor

**WHO Regional Vaccine** 

#### **Advisory Chairperson**

STI vaccine development and strategy Committee

#### Advisor



### Wits Reproductive Health and HIV Institute and Prof Helen Rees

# **Conflicts of Interest**

# **Donors & Partners**

Founder & Director of Wits RHI







































































### Prof Shabir A. Mahdi: A 'Global Élite' Puppet – Positions Held



**Member Scientific Advisory Committee** 



2013 to 2020



Chair: Consultation on GBS **Vaccine Development** 



on development of influenza



Strategic Advisory group Group B streptococcus value proposition



Strategic Advisory Group of **Experts (Vaccines)** 



Working group: Influenza accination of health workers



**Product and Development** /accine Advisory Committe



RSV Vaccine Consultation **Expert Group** 



**Partners** 

**USAID** 

NOVARTIS







**DST/NRF South African Research** Vaccine Preventable Diseases Unit

Chair



BILL&MELINDA GATES foundation

**Scientific Advisory Committee** 



South African ChAdOx1Cov-19 Vaccine Trial

**Principal Investigator** 









**Vaccine Trial** 

**Principal Investigator** 

UNIVERSITY OF THE UNIVERSITY OF THE WITWATERSRAND, IOHANNESBURG

**Director Vaccines and** Infectious Diseases **Analytical Research Unit** 

2020 to present

**Professor of Vaccinology** 







Co-director (2017 to present)



Director: MRC Vaccines and Infectious

Diseases Analytics Research Unit

**Director: MRC Respiratory and** 

**Meningeal Pathogens Research Unit** 

THE WORLD BANK



**Chair National** Advisory Group for Immunization South Africa



**Acting Chief Executive** Officer



**Global Pneumonia Prevention Coalition** 

**Scientific Advisory Group** 

### Prof Shabir A. Mahdi: Principal Vaccinologist - Funding









**Committed Grants** 

Honoraria for Advisory Board Participation

\$750million

GATES foundation

BILL & MELINDA









**Grant ZAR 3,856,600** 

Consultant/Speaker Fees

**Publication Funding** 



**Grant ZAR 3,856,600** 

**Consultant/Speaker Fees** 

**Publication Funding** 





















Scientific Advisor Honoraria payment **Publication Funding** 



ZAR 2.5m | USD 5.8m

**Scientific Advisor** 

Honoraria payment

**Publication Funding** 

**Grant Funding** 

Consultant/Speaker Fees

NOVARTIS



Prof Shabir A. Mahdi Prof of Vaccinology, Univ. of Witwatersrand

Scientific Advisor

Honoraria payment

**Publication Funding** 

**NIHR** 

MedImmune







**Grant Funding** 





Providence

**National Foundation** 

**Future Fund** 

**European and Developing Countries** Clinical Trials Partnership






**Grant Funding** 















### **Product Development for Vaccines Advisory Committee**



Health Topics 🗸

Countries ~

Newsroom ~

Emergencies v

Data 🗸

About Us 🗸

### Strategic Advisory Group of Experts on Immunization, Vaccines and Biologicals (SAGE)



Bernard Fritzell, M.D., M.P.H former Vice-President, International Scientific and Clinical Affairs, Pfizer Vaccines Research



Barney S. Graham, M.D., PhD Senior Investigator at the Vaccine Research Center, NIAID. NIH



Ruth Karron, M.D. CDC
Advisory Committee on
Immunization Practices. FDA
Vaccine and Related Biological
Products Advisory Committee



David C. Kaslow, M.D Vice President, Essential Medicines, and Head, PATH's Center for Vaccine Innovation and AccessVice President and Head of Vaccines Project Leadership and Management at Merck Research Laboratorie National Institute of Allergy and Infectious Diseases (NIAID)



Jerome H. Kim, M.D., Director General of the International Vaccine Institute (IVI) funded by Bill and Melinda Gates Foundation.



Prof. Shabir Madhi, Prof Vaccinology, Wits Univ. Head of SA AstraZeneca ChAdOx1 Trial, Chair of the National Advisory Group for Immunization in South Africa and on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation Global Health Program.



### National Institute for Communicable Diseases, SA Conflicts of Interest





**National Institute for Communicable Diseases** 



# **Prof Lucille Blumberg**

Vice-Chair, WHO Committee for Review of the International Health Regulations during COVID-19





# **Conflicts of Interest**

Division of the National Health Laboratory Service

National Influenza Centre (NIC); and a WHO RSV and SARS-CoV-2 Reference Laboratory






Regional reference laboratory for the World Health Organization (WHO) Vaccine-preventable Invasive Bacterial Diseases (VP-IBD) Coordinated Global Surveillance Network for the Southern African region

# together • COVID-19 trial : Dr Francois Venter

TCI Fund Google

Microsoft



Melinda GATES

consortium

HYGIENE

MEDICINE

Advisor/Funder

World Health

**Organization** 

LSTM /



PEPFAR

Funder

Cipla

MSD MSD

Aids

ANOVA

SECTION2

Fonds



### **Research Funding**



# **Prof Marc Mendelson: "Global Elite Puppet"**





BILL & MELINDA
GATES foundation

Funder



Prof Marc Mendelson

Head of the Division of Infectious Diseases

& HIV Medicine at Groote Schuur Hospital













Participant (Dec 2020)





Antibiotic Working Group

Member (2017 to 2022)



Multiple Technical Advisory Groups on Antimicrobial

Member (2012 – 2022)



**Antimicrobial Resistance** 

Resistance)